You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial being conducted at the Karolinska University Hospital. The aim of the dose escalation clinical trialAlready a subscriber Login…
ALK’s partner MSD has produced encouraging results from a North American Phase III clinical trial of ALK's investigational sublingual allergy immunotherapy tablet for the treatment of house dust mite allergic rhinitis. The trial demonstrated a statistically significant improvement in the primaAlready a subscriber Login You have read all your free articles,…
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. THEMIS was conducted in over 19,Already a subscriber Login You have read all your…
AlzeCure Pharma has received new data from the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, which is being developed against Alzheimer's disease and other indications with cognitive dysfunction. New data from a planned exploratory analysAlready a subscriber Login You have read…
